ACT

NOVEMBER 19/2019

news roundup

WCG Acquires Waife & Associates

WCG has acquired biopharma consultancy Waife & Associates (W&A). W&A will continue to provide analysis, implementations and recommendations to address a range of organizational and technology questions around the clinical development process. W&A's Founder Ronald S. Waife becomes WCG's Chief Management Consulting Officer.


Tufts, Avoca Release Industrywide Benchmarks for the Contract Vendor Qualification Process

The Tufts Center for the Study of Drug Development, in collaboration with The Avoca Group, released its results from the first industrywide benchmarks of the vendor qualification process. Highlights include: vendor requalification cycle times are two to four weeks faster, on average, than new vendor qualifications and despite longer total assessment cycle times, large drug companies have the highest rates of vendors failing to qualify (11.5%), likely due to deeper inquiry into vendor practices.


advertisement

Anti-Microbial Resistance and the Role of Vaccines
Europe: Thursday, November 14, 2019 at 3pm GMT | 4pm CET
North America: Thursday, November 21, 2019 at 11am EST | 10am CST | 8am PST
Register Now



In this edition

The Functional Service Provider (FSP) Model Revisited
2020: The Future Awaits


Subscribe

Subscribe

Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »



Signant Health, ActiGraph Integrate for Real-World Patient Functioning

Signant Health, formerly CRF Health and Bracket, has integrated its eCOA platform TrialMax with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, hopes to simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.


advertisement

Trends and Insights for Your Oncology Trial Tuesday, November 12, 2019 at 10am EST
Register Now


Articles

Cardiac Imaging in Clinical Trials

This article examines imaging systems and services since its use is commonly used as a biomarker for safety in oncology development and in many trials is the primary efficacy endpoint.


The Functional Service Provider (FSP) Model Revisited

The understanding of FSP, how it is evolving and how to get the best results from the model still are a puzzle to many, say the authors. For the purposes of this article, we define FSP as an outsourcing strategy where vendors provide a single service (statistics, pharmacovigilance or clinical monitoring, etc.) or a limited number of highly related services (site contracting, site payments, etc.).

advertisement

Launching Medical Devices in the Japanese Market
How to navigate regulatory and reimbursement approval

On Demand


Please Take Our Salary Survey!


Events

Clinical Trial Legal and Contracting Forum
Clinical Trial Financial Management
Eyeforpharma Awards 2019
Search Upcoming Events

advertisement

Will Decentralized Clinical Trials Compound Patient and Data Quality Risks?

On Demand


Blog Posts

2020: The Future Awaits

Editorial Director Lisa Henderson writes that while industry has touted the statistic on the internal rate of return (IRR) on pharma R&D is predicted to be at 0% in 2020, there are some uplifiting developments around innovation that could erase this bleak prospect.

Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription

Get the full picture


Ask the editor

Lisa Henderson
Editor in Chief
LHenderson@mmhgroup.com

Advertise

Todd Baker
Group Publisher
TBaker@mmhgroup.com